Pubblicazioni scientifiche

Le attività di ricerca traslazionale finalizzate alla messa a punto dei protocolli clinici hanno portato alla stesura di lavori che hanno consentito di essere presenti in convegni nazionali ed internazionali e di pubblicare su riviste internazionali. Qui di seguito si riporta l’elenco dei lavori originali pubblicati su riviste internazionali dal 2008 ad oggi.

  1. Cappuzzello E, Vigolo E, D'Accardio G, Astori G, Rosato A, Sommaggio R. How can Cytokine-induced killer cells overcome CAR-T cell limits. Front Immunol. 2023 Aug 22;14:1229540. doi: 10.3389/fimmu.2023.1229540. PMID: 37675107; PMCID: PMC10477668.
  2. Bozza A, Bernardi M, Catanzaro D, Chieregato K, Merlo A, Astori G. Enalaprilat and losartan decrease erythroid precursors frequency in cells from patients with polycythemia vera. Hematology. 2023 Dec;28(1):2182056. doi: 10.1080/16078454.2023.2182056. PMID: 36856520.
  3. Ciccocioppo R, Guadalajara H, Astori G, Carlino G, García-Olmo D. Misconceptions, hurdles and recommendations regarding the use of mesenchymal stem/stromal cells in perianal Crohn disease. Cytotherapy. 2023 Mar;25(3):230-234. doi: 10.1016/j.jcyt.2022.11.011. Epub 2022 Dec 20. PMID: 36543715.
  4. Marzaro M, Pozzato G, Tedesco S, Algeri M, Pozzato A, Tomao L, Montano I, Torroni F, Balassone V, Contini ACI, Guerra L, D'Angelo T, Federici di Abriola G, Lupoi L, Caristo ME, Boškoski I, Costamagna G, Francalanci P, Astori G, Bozza A, Bagno A, Todesco M, Trovalusci E, Oglio LD, Locatelli F, Caldaro T. Decellularized esophageal tubular scaffold microperforated by quantum molecular resonance technology and seeded with mesenchymal stromal cells for tissue engineering esophageal regeneration. Front Bioeng Biotechnol. 2022 Oct 4;10:912617. doi: 10.3389/fbioe.2022.912617.
  5. Catanzaro D, Milani G, Bozza A, Bernardi M, Chieregato K, Menarin M, Merlo A, Celli P, Belli R, Peroni D, Pozzato A, Pozzato G, Raneri FA, Volpin L, Ruggeri M, Astori G.
    Selective cell cycle arrest in glioblastoma cell lines by quantum molecular resonance alone or in combination with temozolomide. Br J Cancer. 2022 Jun 17. doi: 10.1038/s41416-022-01865-9.
  6. Dalla Pietà A, Cappuzzello E, Palmerini P, Ventura A, Visentin A, Astori G, Chieregato K, Mozzo V, Perbellini O, Tisi MC, Trentin L, Visco C, Ruggeri M, Sommaggio R, Rosato A. Innovative therapeutic strategy for B-cell malignancies that combines obinutuzumab and cytokine-induced killer cells. J Immunother Cancer. 2021 Jul;9(7):e002475. doi: 10.1136/jitc-2021-002475.
  7. Ciccocioppo R, Gibellini D, Astori G, Bernardi M, Bozza A, Chieregato K, Elice F, Ugel S, Caligola S, De Sanctis F, Canè S, Fiore A, Trovato R, Vella A, Petrova V, Amodeo G, Santimaria M, Mazzariol A, Frulloni L, Ruggeri M, Polati E, Bronte V. The immune modulatory effects of umbilical cord-derived mesenchymal stromal cells in severe COVID-19 pneumonia.Stem Cell Res Ther. 2021 Jun 2;12(1):316. doi: 10.1186/s13287-021-02376-9.
  8. Chieregato K, Bernardi M, Alghisi A, Giordano R, Lazzari L, Perbellini O, Rassu M, Ruggeri M, Astori G.A flow cytometric assay for the quantification of MSC lysis by peripheral blood mononucleated cells. Heliyon. 2021 Feb 1;7(2):e06036. doi: 10.1016/j.heliyon.2021.e06036. eCollection 2021 Feb.
  9. Astori G, Bernardi M, Bozza A, Catanzaro D, Chieregato K, Merlo A, Santimaria M, Barbazza R, Amodeo G, Ciccocioppo R, Elice F, Ruggeri M. Logistics of an advanced therapy medicinal product during COVID-19 pandemic in Italy: successful delivery of mesenchymal stromal cells in dry ice. J Transl Med. 2020 Nov 30;18(1):451. doi: 10.1186/s12967-020-02625-0. PMID: 33256746
  10. Ciccocioppo R, Comoli P, Astori G, Del Bufalo F, Prapa M, Dominici M, Locatelli F. Developing cell therapies as drug products. Br J Pharmacol. 2020 Nov 3. doi: 10.1111/bph.15305. Online ahead of print.PMID: 33140850 Review
  11. Dalla Pietà A, Sommaggio R, Ventura A, Astori G, Chieregato K, Tisi MC, Visco C, Perbellini O, Ruggeri M, Cappuzzello E, Rosato A. A serum-free protocol for the ex vivo expansion of Cytokine-Induced Killer cells using gas-permeable static culture flasks.Cytotherapy. 2020 Sep;22(9):511-518.
  12. Marzaro M, Algeri M, Tomao L, Tedesco S, Caldaro T, Balassone V, Contini AC, Guerra L, Federici D'Abriola G, Francalanci P, Caristo ME, Lupoi L, Boskoski I, Bozza A, Astori G, Pozzato G, Pozzato A, Costamagna G, Dall'Oglio L. Successful muscle regeneration by a homologous microperforated scaffold seeded with autologous mesenchymal stromal cells in a porcine esophageal substitution model. Therap Adv Gastroenterol. 2020 May 26;13:1756284820923220.
  13. Barilani M, Banfi F, Sironi S, Ragni E, Guillaumin S, Polveraccio F, Rosso L, Moro M, Astori G, Pozzobon M, Lazzari L. Low-affinity Nerve Growth Factor Receptor (CD271) Heterogeneous Expression in Adult and Fetal Mesenchymal Stromal Cells. Sci Rep. 2018 Jun 18;8(1):9321. doi: 10.1038/s41598-018-27587-8.
  14. Becherucci V, Piccini L, Casamassima S, Bisin S, Gori V, Gentile F, Ceccantini R, De Rienzo E, Bindi B, Pavan P, Cunial V, Allegro E, Ermini S, Brugnolo F, Astori G, Bambi F. Human platelet lysate in mesenchymal stromal cell expansion according to a GMP grade protocol: a cell factory experience. Stem Cell Res Ther. 2018 May 2;9(1):124. doi: 10.1186/s13287-018-0863-8.
  15. Amati E, Perbellini O, Rotta G, Bernardi M, Chieregato K, Sella S, Rodeghiero F, Ruggeri M, Astori G High-throughput immunophenotypic characterization of bone marrow- and cord blood-derived mesenchymal stromal cells reveals common and differentially expressed markers: identification of angiotensin-converting enzyme (CD143) as a marker differentially expressed between adult and perinatal tissue sources. Stem Cell Res Ther. 2018 Jan 16;9(1):10
  16. Sella S, Adami V, Amati E, Bernardi M, Chieregato K, Gatto P, Menarin M, Pozzato A, Pozzato G, Astori G. In-vitro analysis of Quantum Molecular Resonance effects on human mesenchymal stromal cells. PLoS One. 2018 Jan 2;13(1)
  17. Astori G. Advances in the use of cord blood as a potential source of MSCs. Cell Gene Therapy Insights 2017; 3(7), 553-557. DOI: 10.18609/cgti.2017.054
  18. Agostini F, Polesel J, Battiston M, Lombardi E, Zanolin S, Da Ponte A, Astori G, Durante C and Mazzucato M. Standardization of platelet releasate products for clinical applications in cell therapy: a mathematical approach. Journal of Translational Medicine 201715:107
  19. Bernardi M, Agostini F, Chieregato K, Amati E, Durante C, Rassu M, Ruggeri M, Sella S, Lombardi E, Mazzucato M, Astori G. The production method affects the efficacy of platelet derivatives to expand mesenchymal stromal cells in vitro. J Transl Med. 2017 May 1;15(1):90
  20. Amati E, Sella S, Perbellini O, Alghisi A, Bernardi M, Chieregato K, Lievore C, Peserico D, Rigno M, Zilio A, Ruggeri M, Rodeghiero F, Astori G. Generation of mesenchymal stromal cells from cord blood: evaluation of in vitro quality parameters prior to clinical use. Stem Cell Res Ther. 2017 Jan 24;8(1):14
  21. Astori G, Amati E, Bambi F, Bernardi M, Chieregato K, Schäfer R, Sella S, Rodeghiero F. Platelet lysate as a substitute of animal serum for the ex-vivo expansion of mesenchymal stem/stromal cells: present and future. Stem Cell Research & Therapy 2016 Jul 13;7(1):93
  22. Albiero E, Amati E, Baumeister E, Einsele H, Grigoleit GU, Rodeghiero F. Heterogeneity of Specific CD4+ and CD8+ T Cells Stimulated by CMV pp65 and IE1 Antigens. J Immunother. 2016 Nov/Dec;39(9):329-342
  23. Izeta A, Herrera C, Mata R, Astori G, Giordano R, Hernández C, Leyva L, Arias S, Oyonarte S, Carmona G, Cuende N. Cell-based product classification procedure: What can be done differently to improve decisions on borderline products?. 2016 Jul;18(7):809-15
  24. Chieregato K, Zanon C, Castegnaro S, Bernardi M, Amati E, Sella S, Rodeghiero F, Astori G. The cytotoxic action of the CD56+ fraction of cytokine-induced killer cells against a K562 cell line is mainly restricted to the natural killer cell subset. Blood Transfus 2016 Mar 21:1-8
  25. Castegnaro S, Dragone P, Chieregato K, Alghisi A, Rodeghiero F, Astori G. Enumeration of residual white blood cells in leukoreduced blood products: Comparing flow cytometry with a portable microscopic cell counter. Transfus Apher Sci. 2016 Apr;54(2):266-70
  26. Bernardi M, Adami V, Albiero E, Madeo D, Rodeghiero F, Astori G. Absence of micronucleus formation in CHO-K1 cells cultivated in platelet lysate enriched medium. Exp Toxicol Pathol. 2014 Mar; 66(2-3)
  27. Zanon C, Stocchero M, Albiero E, Castegnaro S, Chieregato K, Madeo D, Rodeghiero F, Astori G. Multivariate statistical data analysis as a tool to analyze ex vivo expansion dynamics of cytokine-induced killer cells. Cytometry B Clin Cytom. 2014 Jul; 86(4):257-62
  28. Bernardi M, Albiero E, Alghisi A, Chieregato K, Lievore C, Madeo D, Rodeghiero F, Astori G. Production of human platelet lysate by use of ultrasound for ex vivo expansion of human bone marrow-derived mesenchymal stromal cells. 2013 Aug;15(8):920-9. doi: 10.1016/j.jcyt.2013.01.219. Epub 2013 Apr 24
  29. Chieregato K, Albiero E, Castegnaro S, Bernardi M, d’Amore E, Zanon C, Madeo D, Rodeghiero F and Astori G. A study on mutual interaction between cytokine induced killer cells and umbilical cord-derived mesenchymal cells: implication for their in-vivo use. Blood, Cells, Molecules and Diseases, 2012, 15;49(3-4)
  30. Castegnaro S, Visco C, Chieregato K, Bernardi M, Albiero E, Zanon C, Madeo D, Rodeghiero F. Cytosine arabinoside potentiates the apoptotic effect of bendamustine on several B- and T-cell leukemia/lymphoma cells and cell lines. Leuk Lymphoma. 2012 Nov;53(11):2262-8. doi: 10.3109/10428194.2012.688200. Epub 2012 May 21
  31. Visco C, Castegnaro S, Chieregato K, Bernardi M, Albiero E, Zanon C, Madeo D, Rodeghiero F. The cytotoxic effects of bendamustine in combination with cytarabine in mantle cell lymphoma cell lines. Blood Cells Mol Dis. 2012 Jan 15;48(1):68-75. doi: 10.1016/j.bcmd.2011.09.007. Epub 2011 Oct 2
  32. Albiero E, Ruggeri M, Fortuna S, Finotto S, Bernardi M, Madeo D, Rodeghiero F. Isolated erythrocytosis: study of 67 patients and identification of three novel germ-line mutations in the prolyl hydroxylase domain protein 2 (PHD2) gene. Haematologica. 2012 Jan;97(1):123-7. doi: 10.3324/haematol.2010.039545. Epub 2011 Aug 9
  33. Albiero E, Ruggeri M, Fortuna S, Bernardi M, Finotto S, Madeo D, Rodeghiero F. Analysis of the oxygen sensing pathway genes in familial chronic myeloproliferative neoplasms and identification of a novel EGLN1 germ-line mutation. Br J Haematol. 2011 May;153(3):405-8. doi: 10.1111/j.1365-2141.2010.08551.x. Epub 2011 Jan 31
  34. Chieregato K, Castegnaro S, Madeo D, Astori G, Pegoraro M, Rodeghiero F. Epidermal growth factor, basic fibroblast growth factor and platelet-derived growth factor-bb can substitute for fetal bovine serum and compete with human platelet-rich plasma in the ex vivo expansion of mesenchymal stromal cells derived from adipose tissue. 2011 May 30
  35. Castegnaro S, Chieregato K, Maddalena M, Albiero E, Visco C, Madeo D, Pegoraro M, Rodeghiero F. Effect of platelet lysate on the functional and molecular characteristics of mesenchymal stem cells isolated from adipose tissue. Curr Stem Cell Res Ther. 2011 Jun;6(2):105-14.
  36. Bernardi M, Ruggeri M, Albiero E, Madeo D, Rodeghiero F. Isolated erythrocytosis in V617F negative patients with JAK2 exon 12 mutations: report of a new mutation. Am J Hematol. 2009 Apr;84(4):258-60. doi: 10.1002/ajh.21357
  37. Albiero E, Madeo D, Ruggeri M, Bernardi M, Giorgetti A, Rodeghiero F. Loss of the JAK2 intramolecular auto-inhibition mechanism is predicted by structural modelling of a novel exon 12 insertion mutation in a case of idiopathic erythrocytosis. Br J Haematol. 2008 Sep;142(6):986-90. doi: 10.1111/j.1365-2141.2008.07180.x. Epub 2008 Jul 30
  38. Albiero E, Bernardi M, Madeo D, Ruggeri M, Rodeghiero F. A new TMHA-DHPLC assay for the rapid mutation screening of JAK2 exon 14 in myeloproliferative disorders. Am J Hematol. 2008 Jul;83(7):603-4. doi: 10.1002/ajh.21116